Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States.
Mohile S, Dumontier C, Mian H, Loh KP, Williams GR, Wildes TM, Boyd K, Ramsdale E, Pyne S, Magnuson A, Tew W, Klepin HD, Dale W, Shahrokni A. Mohile S, et al. Among authors: mian h. J Geriatr Oncol. 2020 Jun;11(5):753-760. doi: 10.1016/j.jgo.2020.04.010. Epub 2020 Apr 21. J Geriatr Oncol. 2020. PMID: 32340908 Free PMC article. No abstract available.
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
LeBlanc R, Mian H, Reece D, Su J, Masih-Khan E, Chu M, Jimenez-Zepeda V, Sebag M, Song K, Louzada M, Kotb R, Visram A, White D, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kaedbey R, Gul E, Venner C. LeBlanc R, et al. Among authors: mian h. Eur J Haematol. 2023 Nov;111(5):815-823. doi: 10.1111/ejh.14082. Epub 2023 Aug 13. Eur J Haematol. 2023. PMID: 37574220
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A, Louzada M, Venner CP, Visram A, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, LeBlanc R, Sebag M, Song K, White D, Mian H, Stakiw J, Reiman A, Aslam M, Kotb R, Gul E, Reece D. McCurdy A, et al. Among authors: mian h. EJHaem. 2022 Aug 31;3(4):1252-1261. doi: 10.1002/jha2.559. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467802 Free PMC article.
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S. Bumma N, et al. Among authors: mian h. Cancer. 2023 Jul 15;129(14):2179-2191. doi: 10.1002/cncr.34778. Epub 2023 Apr 6. Cancer. 2023. PMID: 37021929
Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.
Aghel N, Lui M, Wang V, Khalaf D, Mian H, Hillis C, Walker I, Leber B, Lipton JH, Aljama M, Lepic K, Berg T, Garcia-Horton A, Petropoulos J, Masoom H, Leong DP. Aghel N, et al. Among authors: mian h. Bone Marrow Transplant. 2023 May;58(5):478-490. doi: 10.1038/s41409-023-01928-2. Epub 2023 Feb 27. Bone Marrow Transplant. 2023. PMID: 36849807 Review.
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
Visram A, De La Torre A, White D, Su J, Masih-Khan E, Chu M, Jimenez-Zepeda V, McCurdy A, LeBlanc R, Song K, Mian H, Louzada M, Sebag M, Bergstrom D, Stakiw J, Reiman A, Kotb R, Aslam M, Venner C, Kaedbey R, Gul E, Reece D. Visram A, et al. Among authors: mian h. Blood Cancer J. 2023 Dec 8;13(1):181. doi: 10.1038/s41408-023-00946-z. Blood Cancer J. 2023. PMID: 38065967 Free PMC article.
109 results